Glutamate-based Therapies for Psychiatric Disorders

  • Phil Skolnick

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Phil Skolnick, Piotr Popik, Ramon Trullas
    Pages 1-20
  3. Bernadeta Szewczyk, Ewa Poleszak, Andrzej Pilc, Gabriel Nowak
    Pages 21-38
  4. Joanna M. Wieronska, Gabriel Nowak, Andrzej Pilc
    Pages 157-173
  5. Back Matter
    Pages 175-178

About this book

Introduction

Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.

Keywords

Nervous System antidepressant effect brain brain injury depression drug drug abuse psychiatric disorder receptor research schizophrenia therapy trauma traumatic brain injury zinc

Editors and affiliations

  • Phil Skolnick
    • 1
  1. 1.Div Pharmacotherapies & Medical ConsequeNational Institute on Drug AbuseRockvilleUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-0346-0241-9
  • Copyright Information Springer Basel AG 2010
  • Publisher Name Birkhäuser, Basel
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-0346-0240-2
  • Online ISBN 978-3-0346-0241-9
  • About this book